stockrowVivoSim Labs, Inc.
VIVS Healthcare Biotechnology
VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025.
- Revenue
- −51.4%
- EPS
- +78.1%
- Free cash flow
- +17.9%
Quarter to June 2026, against a year earlier
Follow VIVS
Alert me
VivoSim Labs, Inc. (VIVS) EV/Sales
As of 6 November 2026, VivoSim Labs, Inc. (VIVS) trades at a EV/Sales of −8.4×. Over the past ten years it has ranged from −64.2× (June 2025) to 1,280× (January 2015); the current reading is higher than 6% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | −10.1× | — |
| FY2025 | −55.8× | — |
| FY2024 | 27.4× | 1,570.91% |
| FY2023 | 1.6× | 23.03% |
| FY2022 | 1.3× | (88.62%) |
| FY2020 | 11.7× | (51.77%) |
| FY2019 | 24.3× | 92.43% |
| FY2018 | 12.6× | (78.46%) |
| FY2017 | 58.6× | (34.75%) |
| FY2016 | 89.9× | (77.85%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 35.1× | — |
| Mar 2026 | −10.1× | — |
| Dec 2025 | 3.1× | (54.07%) |
| Sep 2025 | 6.6× | — |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VIVS VivoSim Labs, Inc. | −8.4× |
| BRTX Biorestorative Therapies, Inc. compare | −5.8× |
| EOCN Eocene Ltd. compare | −3.1× |
| APVO Aptevo Therapeutics Inc. compare | −0.4× |
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| SLXN Silexion Therapeutics Corp compare | n/m |
| HCWB HCW Biologics Inc. compare | 1.1× |
| WINT Windtree Therapeutics, Inc. compare | 63.8× |
| BIORQ Biora Therapeutics, Inc. compare | 67.4× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)